Epicardial Adipose Tissue in Myocardial Disease: From Physiology to Heart Failure Phenotypes

Curr Probl Cardiol. 2023 Oct;48(10):101841. doi: 10.1016/j.cpcardiol.2023.101841. Epub 2023 May 26.

Abstract

Epicardial adipose tissue (EAT) is increasingly being recognized as a determinant of myocardial biology. The EAT-heart crosstalk suggests causal links between dysfunctional EAT and cardiomyocyte impairment. Obesity promotes EAT dysfunction and shifts in secreted adipokines which adversely affect cardiac metabolism, induce cardiomyocyte inflammation, redox imbalance and myocardial fibrosis. Thus, EAT determines cardiac phenotype via effects on cardiac energetics, contractility, diastolic function, and atrial conduction. Vice-versa the EAT is altered in heart failure (HF), and such phenotypic changes can be detected by noninvasive imaging or incorporated in Artificial Intelligence-enhanced tools to aid the diagnosis, subtyping or risk prognostication of HF. In the present article, we summarize the links between EAT and the heart, explaining how the study of epicardial adiposity can improve the understanding of cardiac disease, serve as a source of diagnostic and prognostic biomarkers, and as a potential therapeutic target in HF to improve clinical outcomes.

Publication types

  • Review

MeSH terms

  • Adipose Tissue / metabolism
  • Artificial Intelligence
  • Cardiomyopathies*
  • Heart Failure* / diagnosis
  • Heart Failure* / etiology
  • Heart Failure* / metabolism
  • Humans
  • Obesity / complications
  • Pericardium / metabolism
  • Phenotype